First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Aaron S. Mansfield et al.|New England Journal of Medicine|2018Cited by 3.5k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Sarah Paul et al.|Nature Medicine|2018Cited by 1.2k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|Nature|2021Cited by 603
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Lin Wu, Yi‐Long Wu et al.|Clinical Cancer Research|2015Cited by 469